The resulting computational workflow, called GENERA, was applied to the de novo inhibitor design of angiotensin-convertingenzyme 2 (ACE2), which plays a crucial role in various pathologicalconditions, including COVID-19. This evidence concerns the gene ACE2 and COVID-19.